Foundation Medicine to Present New Data on FoundationOne™, a Comprehensive Cancer Genomic Assay, at the 14th Annual AGBT Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that new data on the clinical validation and application of FoundationOne™ will be presented at the 14th Annual Advances in Genome Biology and Technology (AGBT) Meeting taking place February 20-23, 2013 in Marco Island, Fla.

Phil Stephens, Ph.D., vice president, cancer genomics at Foundation Medicine, has been selected to give the closing address of the conference. In his remarks, Dr. Stephens will present details on the clinical experience derived from the genomic profiling of more than 1,000 tumor samples using FoundationOne.

The schedule for Foundation Medicine’s presentations is as follows:

Date & Time: Thursday, February 21, 2013 from 1:00 p.m. to 2:30 p.m. EST

Title: Validation of a Million Base-pair Cancer Profiling Assay for Clinical Use

Session: Poster Session

Location: Poster No. 159, Collier Hall

Presenter: Doron Lipson, Ph.D., Foundation Medicine

Date & Time: Friday, February 22, 2013 at 7:50 p.m. EST

Title: Genomic and cDNA Next Generation Sequencing Identifies a High Frequency of Kinase Gene Fusions in Spitz Tumors

Session: Concurrent Session: Cancer Genomics

Location: Islands Ballroom

Presenter: Geoff Otto, Ph.D., Foundation Medicine

Date & Time: Saturday, February 23, 2013 at 4:00 p.m. EST

Title: Comprehensive Genomic Profiling of 1,000+ Consecutive FFPE Tumors using a Next Generation Sequencing (NGS) Diagnostic Assay in a CLIA Certified Lab: Translating NGS into the Clinic

Session: Plenary Session: Genomic Studies III

Location: Islands Ballroom

Presenter: Phil Stephens, Ph.D., Foundation Medicine

About Foundation Medicine

Foundation Medicine^® is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical assay, FoundationOne^TM, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark, and FoundationOne^TM is a trademark, of Foundation Medicine, Inc.